Anti-tumor compounds

University at Buffalo - The State University of New York
posted on 10/20/2009

Members of the inhibitor of apoptosis protein (IAP) protein family are often expressed at high levels in cancer cells. It is thought that high expression of IAP proteins leads to a disruption in the apoptotic pathway (programmed cell death). This disruption allows for continuation of the cell cycle and thus proliferation of tumor cells. XIAP and survivin are two members of the IAP protein family. It is thought that drugs or compounds that inhibit such proteins will allow for the cell to return to a normal cellular apoptotic pathway and prevent cancerous cell growth. Using molecular modeling techniques from the crystal structure of XIAP, researchers at the University at Buffalo and Roswell Park Cancer Institute have developed and tested compounds that inhibit cell growth in prostate cancer and breast cancer cell lines.

Detailed Description

Members of the inhibitor of apoptosis protein (IAP) protein family are often expressed at high levels in cancer cells. It is thought that high expression of IAP proteins leads to a disruption in the apoptotic pathway (programmed cell death). This disruption allows for continuation of the cell cycle and thus proliferation of tumor cells. XIAP and survivin are two members of the IAP protein family. It is thought that drugs or compounds that inhibit such proteins will allow for the cell to return to a normal cellular apoptotic pathway and prevent cancerous cell growth. Using molecular modeling techniques from the crystal structure of XIAP, researchers at the University at Buffalo and Roswell Park Cancer Institute have developed and tested compounds that inhibit cell growth in prostate cancer and breast cancer cell lines.

File Number: 6140

Disease: Cancer

Other Information: Principal Investigator: David Hangauer

This innovation currently is not available for online licensing. Please contact Tim Dee at University at Buffalo - The State University of New York for more information.

request more info

Anti-tumor compounds

Alan Thomas, Director, UChicagoTech